Prevention of glucocorticoid induced bone changes with beta-ecdysone

Bone

Volumn 74, Issue , 2015, Pages 48-57

  Dai, Weiwei ^a,b   Jiang, Li ^a   Lay, Yu An Evan ^a   Chen, Haiyan ^a   Jin, Guoqin ^b   Zhang, Hongliang ^a   Kot, Alexander ^a   Ritchie, Robert O ^c   Lane, Nancy E ^a   Yao, Wei ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c University of California Berkeley   (United States)

Author keywords

Autophagy; Beta ecdysone ( Ecd); Bone formation; Glucocorticoid

Indexed keywords

ECDYSTERONE; PLACEBO; PREDNISOLONE; GLUCOCORTICOID; HORMONE;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BONE CELL; BONE GROWTH; BONE MARROW STROMA CELL; BONE MASS; CELL VIABILITY; CONTROLLED STUDY; CORTICAL BONE; DRUG PELLET; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PERIOSTEUM; SWISS WEBSTER MOUSE; TRABECULAR BONE; TREATMENT DURATION; ANIMAL; BIOMECHANICS; BLOOD; BODY WEIGHT; BONE; BONE DEVELOPMENT; BONE REMODELING; CELL DIFFERENTIATION; DRUG EFFECTS; MESENCHYMAL STROMA CELL; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; ORGAN SIZE; OSTEOBLAST; PATHOLOGY; PATHOPHYSIOLOGY; RADIATION RESPONSE; RADIOGRAPHY;

ANIMALS; AUTOPHAGY; BIOMECHANICAL PHENOMENA; BODY WEIGHT; BONE AND BONES; BONE REMODELING; CELL DIFFERENTIATION; ECDYSTERONE; GLUCOCORTICOIDS; HORMONES; MALE; MESENCHYMAL STROMAL CELLS; MICE; ORGAN SIZE; OSTEOBLASTS; OSTEOGENESIS; X-RAY MICROTOMOGRAPHY;

EID: 84921512406     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.01.001     Document Type: Article

References (69)

1. Goemaere S., Liberman U.A., Adachi J.D., Hawkins F., Lane N., Saag K.G., et al. Incidence of nonvertebral fractures in relation to time on treatment and bone density in glucocorticoid-treated patients: a retrospective approach. J Clin Rheumatol 2003, 9:170-175.
2. Silverman S.L., Lane N.E. Glucocorticoid-induced osteoporosis. Curr Osteoporos Rep 2009, 7:23-26.
3. Chiodini I., Carnevale V., Torlontano M., Fusilli S., Guglielmi G., Pileri M., et al. Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome. J Clin Endocrinol Metab 1998, 83:1863-1867.
4. Michaud K., Forget H., Cohen H. Chronic glucocorticoid hypersecretion in Cushing's syndrome exacerbates cognitive aging. Brain Cogn 2009, 71:1-8.
5. Sorva R., Turpeinen M., Juntunen-Backman K., Karonen S.L., Sorva A. Effects of inhaled budesonide on serum markers of bone metabolism in children with asthma. J Allergy Clin Immunol 1992, 90:808-815.
6. Leonard M.B. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 2007, 119(Suppl. 2):S166-S174.
7. Burnham J.M., Shults J., Semeao E., Foster B., Zemel B.S., Stallings V.A., et al. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res 2004, 19:1961-1968.
8. Root A.W., Bongiovanni A.M., Eberlein W.R. Studies of the secretion and metabolic effects of human growth hormone in children with glucocorticoid-induced growth retardation. J Pediatr 1969, 75:826-832.
9. Allen D.B., Julius J.R., Breen T.J., Attie K.M. Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab 1998, 83:2824-2829.
10. Saag K.G., Emkey R., Schnitzer T.J., Brown J.P., Hawkins F., Goemaere S., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med 1998, 339:292-299.
11. Saag K.G., Shane E., Boonen S., Marin F., Donley D.W., Taylor K.A., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
12. Reid D.M., Devogelaer J.P., Saag K., Roux C., Lau C.S., Reginster J.Y., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009, 373:1253-1263.
13. Lane N.E., Sanchez S., Modin G.W., Genant H.K., Pierini E., Arnaud C.D. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998, 102:1627-1633.
14. Inoue Y., Shimojo N., Suzuki S., Arima T., Tomiita M., Minagawa M., et al. Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. Clin Rheumatol 2008, 27:909-912.
15. Henderson S., Hoffman N., Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 2006, 101:119-123.
16. Roldan E.J., Pasqualini T., Plantalech L. Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients. J Pediatr Endocrinol Metab 1999, 12:555-559.
17. Rudge S., Hailwood S., Horne A., Lucas J., Wu F., Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 2005, 44:813-818.
18. Brown J.J., Zacharin M.R. Proposals for prevention and management of steroid-induced osteoporosis in children and adolescents. J Paediatr Child Health 2005, 41:553-557.
19. Papapoulos S.E., Cremers S.C. Prolonged bisphosphonate release after treatment in children. N Engl J Med 2007, 356:1075-1076.
20. Hansen K.E., Wilson H.A., Zapalowski C., Fink H.A., Minisola S., Adler R.A. Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res 2011, 26:1989-1996.
21. Badisco L., Van Wielendaele P., Vanden Broeck J. Eat to reproduce: a key role for the insulin signaling pathway in adult insects. Front Physiol 2013, 4:202.
22. Boo K.H., Lee D., Jeon G.L., Ko S.H., Cho S.K., Kim J.H., et al. Distribution and biosynthesis of 20-hydroxyecdysone in plants of Achyranthes japonica Nakai. Biosci Biotechnol Biochem 2010, 74:2226-2231.
23. Slama K., Koudela K., Tenora J., Mathova A. Insect hormones in vertebrates: anabolic effects of 20-hydroxyecdysone in Japanese quail. Experientia 1996, 52:702-706.
24. Gorelick-Feldman J., MacLean D., Ilic N., Poulev A., Lila M.A., Cheng D., et al. Phytoecdysteroids increase protein synthesis in skeletal muscle cells. J Agric Food Chem 2008, 56:3532-3537.
25. Esposito D., Komarnytsky S., Shapses S., Raskin I. Anabolic effect of plant brassinosteroid. FASEB J 2011, 25:3708-3719.
26. Cheng D.M., Kutzler L.W., Boler D.D., Drnevich J., Killefer J., Lila M.A. Continuous infusion of 20-hydroxyecdysone increased mass of triceps brachii in C57BL/6 mice. Phytother Res 2013, 27:107-111.
27. Esposito D., Rathinasabapathy T., Poulev A., Komarnytsky S., Raskin I. Akt-dependent anabolic activity of natural and synthetic brassinosteroids in rat skeletal muscle cells. J Med Chem 2011, 54:4057-4066.
28. Toth N., Szabo A., Kacsala P., Heger J., Zador E. 20-Hydroxyecdysone increases fiber size in a muscle-specific fashion in rat. Phytomedicine 2008, 15:691-698.
29. Lafont R., Dinan L. Practical uses for ecdysteroids in mammals including humans: an update. J Insect Sci 2003, 3:7.
30. Gao L., Cai G., Shi X. Beta-ecdysterone induces osteogenic differentiation in mouse mesenchymal stem cells and relieves osteoporosis. Biol Pharm Bull 2008, 31:2245-2249.
31. Kapur P., Wuttke W., Jarry H., Seidlova-Wuttke D. Beneficial effects of beta-Ecdysone on the joint, epiphyseal cartilage tissue and trabecular bone in ovariectomized rats. Phytomedicine 2010, 17:350-355.
32. Seidlova-Wuttke D., Christel D., Kapur P., Nguyen B.T., Jarry H., Wuttke W. Beta-ecdysone has bone protective but no estrogenic effects in ovariectomized rats. Phytomedicine 2010, 17:884-889.
33. Leonard M.B., Feldman H.I., Shults J., Zemel B.S., Foster B.J., Stallings V.A. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 2004, 351:868-875.
34. Yao W., Cheng Z., Busse C., Pham A., Nakamura M.C., Lane N.E. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 2008, 58:1674-1686.
35. Lane N.E., Yao W., Balooch M., Nalla R.K., Balooch G., Habelitz S., et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 2006, 21:466-476.
36. Yao W., Guan M., Jia J., Dai W., Lay Y.A., Amugongo S., et al. Reversing bone loss by directing mesenchymal stem cells to bone. Stem Cells 2013, 31:2003-2014.
37. Guan M., Yao W., Liu R., Lam K.S., Nolta J., Jia J., et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med 2012, 18:456-462.
38. Yao W., Dai W., Shahnazari M., Pham A., Chen Z., Chen H., et al. Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice. PLoS One 2010, 5:e11410.
39. Yao W., Cheng Z., Shahnazari M., Dai W., Johnson M.L., Lane N.E. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates PTH bone anabolic effects. J Bone Miner Res 2010, 25:190-199.
40. Dempster D.W., Compston J.E., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 2013, 28:2-17.
41. Yao W., Cheng Z., Pham A., Busse C., Zimmermann E.A., Ritchie R.O., et al. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 2008, 58:3485-3497.
42. Turner C.H., Burr D.B. Basic biomechanical measurements of bone: a tutorial. Bone 1993, 14:595-608.
43. Yao W., Cheng Z., Shahnazari M., Dai W., Johnson M.L., Lane N.E. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res 2010, 25:190-199.
44. Jia J., Yao W., Guan M., Dai W., Shahnazari M., Kar R., et al. Glucocorticoid dose determines osteocyte cell fate. FASEB J 2011, 25:3366-3376.
45. Liu Y., Shoji-Kawata S., Sumpter R.M., Wei Y., Ginet V., Zhang L., et al. Autosis is a Na+, K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc Natl Acad Sci U S A 2013, 110:20364-20371.
46. Balooch G., Yao W., Ager J.W., Balooch M., Nalla R.K., Porter A.E., et al. The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids. Arthritis Rheum 2007, 56:3726-3737.
47. Devogelaer J.P., Sambrook P., Reid D.M., Goemaere S., Ish-Shalom S., Collette J., et al. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. Rheumatology (Oxford) 2013, 52:1058-1069.
48. Gluer C.C., Marin F., Ringe J.D., Hawkins F., Moricke R., Papaioannu N., et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 2013, 28:1355-1368.
49. Saag K.G., Zanchetta J.R., Devogelaer J.P., Adler R.A., Eastell R., See K., et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009, 60:3346-3355.
50. Jacobs J.W., de Nijs R.N., Lems W.F., Geusens P.P., Laan R.F., Huisman A.M., et al. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. J Rheumatol 2007, 34:1051-1057.
51. Stoch S.A., Saag K.G., Greenwald M., Sebba A.I., Cohen S., Verbruggen N., et al. Once-weekly oral alendronate 70mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 2009, 36:1705-1714.
52. Kaji H., Kuroki Y., Murakawa Y., Funakawa I., Funasaka Y., Kanda F., et al. Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study. Osteoporos Int 2010, 21:1565-1571.
53. Sambrook P.N., Roux C., Devogelaer J.P., Saag K., Lau C.S., Reginster J.Y., et al. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone 2012, 50:289-295.
54. Shahnazari M., Yao W., Dai W., Wang B., Ionova-Martin S.S., Ritchie R.O., et al. Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats. Bone 2010, 46:1267-1274.
55. Van Staa T.P., Laan R.F., Barton I.P., Cohen S., Reid D.M., Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48:3224-3229.
56. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. American Society for B, Mineral R. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
57. Papapoulos S.E., Schimmer R.C. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis 2007, 66:853-858.
58. Kruzic J.J., Ritchie R.O. Comments on "Measurement of the microstructural fracture toughness of cortical bone using indentation fracture". J Biomech 2008, 41:1379-1380.
59. Saag K.G. Bone safety of low-dose glucocorticoids in rheumatic diseases. Ann N Y Acad Sci 2014, 1318:55-64.
60. Hock J.M. Anabolic actions of PTH in the skeletons of animals. J Musculoskelet Neuronal Interact 2001, 2:33-47.
61. Peschel W., Kump A., Prieto J.M. Effects of 20-hydroxyecdysone, Leuzea carthamoides extracts, dexamethasone and their combinations on the NF-κB activation in HeLa cells. J Pharm Pharmacol 2011, 63:1483-1495.
62. Riddiford L.M., Cherbas P., Truman J.W. Ecdysone receptors and their biological actions. Vitam Horm 2000, 60:1-73.
63. Lapenna S., Friz J., Barlow A., Palli S.R., Dinan L., Hormann R.E. Ecdysteroid ligand-receptor selectivity-exploring trends to design orthogonal gene switches. FEBS J 2008, 275:5785-5809.
64. Bathori M. Phytoecdysteroids effects on mammalians, isolation and analysis. Mini Rev Med Chem 2002, 2:285-293.
65. Toth N., Hunyadi A., Bathori M., Zador E. Phytoecdysteroids and vitamin D analogues-similarities in structure and mode of action. Curr Med Chem 2010, 17:1974-1994.
66. Zheng B., Ohkawa S., Li H., Roberts-Wilson T.K., Price S.R. FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J 2010, 24:2660-2669.
67. Sapolsky R.M., Krey L.C., McEwen B.S. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci 1985, 5:1222-1227.
68. Xia X., Kar R., Gluhak-Heinrich J., Yao W., Lane N.E., Bonewald L.F., et al. Glucocorticoid induced autophagy in osteocytes. J Bone Miner Res 2010, 25:2479-2488.
69. Onal M., Piemontese M., Xiong J., Wang Y., Han L., Ye S., et al. Suppression of autophagy in osteocytes mimics skeletal aging. J Biol Chem 2013, 288:17432-17440.